Finoriq research workspace
Apogee Therapeutics, Inc. (APGE) SEC Filings & Filing Highlights
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for. Review APGE SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
- Company
- Apogee Therapeutics, Inc. (APGE)
- Ticker
- APGE
- Market Cap
- $10.1B
- Latest Price
- $134.18
- Industry
- Biotech & Pharma
Apogee Therapeutics, Inc. (APGE) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Apogee Therapeutics, Inc. (APGE).
| Event | Form | Date |
|---|---|---|
| AbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio | 8-K8.01 | 2026-06-22 |
| AbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio | 8-K7.01 | 2026-06-22 |
| Apogee Therapeutics, Inc.: Shareholder voteImmediately prior to the execution and delivery of the Merger Agreement, holders of the non-voting common stock of the Company executed and... | 8-K5.07 | 2026-06-22 |
| Agreement and Plan of MergerOn June 18, 2026, Apogee Therapeutics, Inc. (the “Company” or “Apogee”) entered into an Agreement and Plan of Merger (the “Merger Agreement... | 8-K1.01 | 2026-06-22 |
| IL-31R Antibody Discovery AgreementOn June 17, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an antibody discovery agreement with Paragon Therapeutics, Inc. (“... | 8-K1.01 | 2026-06-22 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.